聖湘生物(688289.SH):擬與關聯人戴立忠共同投資長沙榮泉
格隆匯1月11日丨聖湘生物(688289.SH)公佈,為進一步推動公司業務拓展及產業鏈延伸,完善公司在生物醫療領域的綜合戰略佈局,公司擬與關聯人戴立忠共同投資長沙榮泉創業投資有限公司(“長沙榮泉”)。
此次投資完成後,公司持有長沙榮泉30%的股權,其中:公司以人民幣85.71萬元的對價取得長沙榮泉8.571%的股權(對應註冊資本人民幣85.71萬元,已實繳);以人民幣0元的對價取得長沙榮泉21.429%的股權(對應註冊資本人民幣214.29萬元,尚未實繳),並承擔上述未實繳註冊資本人民幣214.29萬元的實繳出資義務。
此次投資長沙榮泉,有助於推進公司在生物醫療領域的全產業鏈佈局,充分發揮雙方優勢,有效形成互補。生物醫療領域技術多樣、專業度高,需要對項目進行專業的技術判斷和底層邏輯分析,有較高的准入門檻。聖湘生物作為以產品和技術為導向的創新性公司,依託專業知識和產業經驗,對前瞻性、卡脖子技術擁有專業敏感度和權威的技術判斷。長沙榮泉管理層具有多年的投資專業經驗和成熟的管理模式,可充分提升公司在項目融資、投資、管理等方面的效率及質量,進行有效的分析和判斷,提升專業化運作水平。雙方可通過投資孵化、收購併購、資產重組等多種方式,引進培育高端產業項目,引進產業高端人才,推動創新鏈、產業鏈、資金鍊、人才鏈深度融合,打造共生共榮的產業生態,推動中國生命科學產業向更高層次、更高水平發展,搶佔全球行業制高點,加速向全球輸出醫療健康領域“中國方案”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.